Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 March 1999Website:
http://www.lisata.comNext earnings report:
28 February 2025Last dividends:
28 October 2013Next dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:21:40 GMTDividend
Analysts recommendations
Institutional Ownership
LSTA Latest News
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for its unique approach to addressing the unmet medical needs of patients with advanced solid tumors, particularly through its proprietary CendR Platform technology which enhances the delivery and efficacy of anti-cancer treatments by targeting the tumor microenvironment.
Award recognizes Lisata's data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon.
Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts projected over the next 18 months. Lisata's financial performance for the quarter showed a 10.5% year-over-year decrease in operating expenses, down to $5.3 million from $6 million.
Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have announced a preclinical research collaboration to explore a novel cancer treatment combination targeting melanoma. Under the collaboration, Valo Therapeutics will lead research investigating the potential benefits of combining Lisata's experimental drug, certepetide, with Valo's PeptiCRAd immunotherapy platform and a checkpoint inhibitor.
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment. Dr Buck highlighted Certepetide, Lisata's novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.
Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
- 1(current)
- 2
What type of business is Lisata Therapeutics?
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
What sector is Lisata Therapeutics in?
Lisata Therapeutics is in the Healthcare sector
What industry is Lisata Therapeutics in?
Lisata Therapeutics is in the Biotechnology industry
What country is Lisata Therapeutics from?
Lisata Therapeutics is headquartered in United States
When did Lisata Therapeutics go public?
Lisata Therapeutics initial public offering (IPO) was on 01 March 1999
What is Lisata Therapeutics website?
https://www.lisata.com
Is Lisata Therapeutics in the S&P 500?
No, Lisata Therapeutics is not included in the S&P 500 index
Is Lisata Therapeutics in the NASDAQ 100?
No, Lisata Therapeutics is not included in the NASDAQ 100 index
Is Lisata Therapeutics in the Dow Jones?
No, Lisata Therapeutics is not included in the Dow Jones index
When was Lisata Therapeutics the previous earnings report?
No data
When does Lisata Therapeutics earnings report?
The next expected earnings date for Lisata Therapeutics is 28 February 2025